AMILI
AMILI is a precision gut microbiome company that translates microbiome science into personalized, clinically-informed solutions for gut and overall health. The company offers at-home gut microbiome test kits, targeted probiotics for immune-metabolic, brain and cognitive, and digestive health, and microbiome restoration therapy. Its Optimise Plus program combines microbiome profiling with real-time glucose response…
Funding snapshot
About
AMILI is a precision gut microbiome company that translates microbiome science into personalized, clinically-informed solutions for gut and overall health. The company offers at-home gut microbiome test kits, targeted probiotics for immune-metabolic, brain and cognitive, and digestive health, and microbiome restoration therapy. Its Optimise Plus program combines microbiome profiling with real-time glucose response and wearable data to deliver personalized nutrition and lifestyle plans guided by dedicated nutritionists. AMILI operates Asia's largest multi-ethnic gut microbiome database with over 10,000 guts profiled and 200+ partner clinics across the region. Founded in 2019 and headquartered in Singapore, the company has raised $10.5 million in Series A funding from investors including East Ventures, Vulcan Capital, Pruksa, Emtek, SEEDS Capital, and TVM Capital Healthcare.
Business model
Genomics > Applied Genomics > Clinical Genomics > Diagnostics > Sequencing-based > Microbial Testing > Microbiomics,
Nutraceuticals Tech > Dietary Supplements > Disease Specific > Diversified
Team background
College Wise > National University of Singapore (NUS), The University of New South Wales
Institutional investors
Backed by funds in our directory
Latest coverage
No articles yet.
Similar startups
Immuneel
Developer of T-cell therapies for the treatment of cancer. It is developing cell therapies by using genetic engineering that modifies healthy immune cells to target cancerous cells.
ImmunoACT
Developer of cell and gene therapies for cancer treatment. It offers a lead product NexCAR19 Talicabtagene autoleucel for B‑cell malignancies such as B‑lymphoma and B‑acute lymphoblastic leukaemia.
HaystackAnalytics
EmbeDL is a provider of an edge AI optimization and deployment platform that streamlines the path from deep learning model development to hardware-ready deployment on embedded systems.
4baseCare
Sitehop is a provider of hardware-enforced network encryption solutions that delivers ultra-low latency, quantum-ready encryption for data-in-motion in critical networks through its SAFE Series product line.